Molecular biology of botulinum neurotoxin serotype A: A cosmetic perspective

Journal of Cosmetic Dermatology

Volumn 7, Issue 3, 2008, Pages 221-225

  Eapen, Bell Raj ^a  

^a Kaya Skin Clinic   (United Arab Emirates)

Author keywords

BoNT A; Botulinum toxin

Indexed keywords

2,4 DICHLOROCINNAMIC HYDROXAMATE; BOTULINUM TOXIN A; BOTULINUM TOXIN E; CINNAMIC ACID DERIVATIVE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; ZINC;

AMINO ACID SEQUENCE; ARTICLE; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOCYTOSIS; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; EXOCYTOSIS; IMMUNE RESPONSE; LETHAL DOSE; NERVE SPROUTING; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

BEAUTY CULTURE; BOTULINUM TOXIN TYPE A; FACE; HUMANS; HYPERHIDROSIS; NEUROMUSCULAR AGENTS; SKIN AGING; TREATMENT OUTCOME;

EID: 48949105287     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2008.00392.x     Document Type: Article

References (36)

1. Hanson D. Botulinum toxin: A bioterrorism weapon. Emerg Med Serv 2004; 33: 55-9.
2. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285: 1059-70.
3. Agarwal R, Eswaramoorthy S, Kumaran D, Binz T, Swaminathan S. Structural analysis of botulinum neurotoxin type E catalytic domain and its mutant Glu212.→.Gln reveals the pivotal role of the Glu212 carboxylate in the catalytic pathway. Biochemistry 2004; 43: 6637-44.
4. Agarwal R, Binz T, Swaminathan S. Structural analysis of botulinum neurotoxin serotype F light chain: Implications on substrate binding and inhibitor design. Biochemistry 2005; 44: 11758-65.
5. Arndt JW, Chai Q, Christian T, Stevens RC. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: Repercussions for VAMP-2 substrate specificity. Biochemistry 2006; 45: 3255-62.
6. Arndt JW, Yu W, Bi F, Stevens RC. Crystal structure of botulinum neurotoxin type G light chain: Serotype divergence in substrate recognition. Biochemistry 2005; 44: 9574-80.
7. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998; 5: 898-902.
8. Swaminathan S, Eswaramoorthy S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 2000; 7: 693-9.
9. Pandya N, Pandya-Sheth S. Cosmetic uses of botox. Int Surg 2006; 91: 117-22.
10. Khanna S, Jain S. Botox: The poison that heals. Int Dent J 2006; 56: 356-8.
11. Krieglstein KG, DasGupta BR, Henschen AH. Covalent structure of botulinum neurotoxin type A: Location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J Protein Chem 1994; 13: 49-57.
12. Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006; 312: 592-6.
13. Breidenbach MA, Brunger AT. New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med 2005; 11: 377-81.
14. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96: 105-13.
15. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200-5.
16. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: The extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003; 22: 454-66.
17. Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun 2001; 69: 6511-4.
18. Bukrinsky JT, Bjerrum MJ, Kadziola A. Native carboxypeptidase A in a new crystal environment reveals a different conformation of the important tyrosine 248. Biochemistry 1998; 37: 16555-64.
19. Arndt JW, Jacobson MJ, Abola EE, et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J.Mol Biol 2006; 362: 733-42.
20. Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994; 269: 1617-20.
21. Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004; 432: 925-9.
22. Silvaggi NR, Boldt GE, Hixon MS, et al. Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol 2007; 14: 533-42.
23. Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg 2002; 26: 356-9.
24. Lawrence GW, Foran P, Mohammed N, DasGupta BR, Dolly JO. Importance of two adjacent C-terminal sequences of SNAP-25 in exocytosis from intact and permeabilized chromaffin cells revealed by inhibition with botulinum neurotoxins A and E. Biochemistry 1997; 36: 3061-7.
25. Neale EA, Bowers LM, Jia M, Bateman KE, Williamson LC. Botulinum neurotoxin A blocks synaptic vesicle exocytosis but not endocytosis at the nerve terminal. J Cell Biol 1999; 147: 1249-60.
26. Ryan TA. Endocytosis at nerve terminals: Timing is everything. Neuron 1996; 17: 1035-7.
27. Zucker RS. Exocytosis: A molecular and physiological perspective. Neuron 1996; 17: 1049-55.
28. Yiadom KP, Muhie S, Yang DC. Peptide inhibitors of botulinum neurotoxin by mRNA display. Biochem Biophys Res Commun 2005; 335: 1247-53.
29. Burnett JC, Schmidt JJ, Stafford RG, et al. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun 2003; 310: 84-93.
30. Sheridan RE, Deshpande SS, Nicholson JD, Adler M. Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin. Toxicon 1997; 35: 1439-51.
31. Deshpande SS, Sheridan RE, Adler M. Efficacy of certain quinolines as pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon 1997; 35: 433-45.
32. Hayden J, Pires J, Roy S, Hamilton M, Moore GJ. Discovery and design of novel inhibitors of botulinus neurotoxin A: Targeted "hinge" peptide libraries. J Appl Toxicol 2003; 23: 1-7.
33. Burnett JC, Schmidt JJ, McGrath CF, et al. Conformational sampling of the botulinum neurotoxin serotype A light chain: Implications for inhibitor binding. Bioorg Med Chem 2005; 13: 333-41.
34. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 2006; 34 (Database issue): D354-7.
35. Hattori M, Okuno Y, Goto S, Kanehisa M. Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. J Am Chem Soc 2003; 125: 11853-65.
36. Flynn TC. Botox in men. Dermatol Ther 2007; 20: 407-13.